摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

7-(piperidin-4-yloxy)-3,4-dihydroquinolin-2(1H)-one | 583031-08-7

中文名称
——
中文别名
——
英文名称
7-(piperidin-4-yloxy)-3,4-dihydroquinolin-2(1H)-one
英文别名
7-piperidin-4-yloxy-3,4-dihydro-1H-quinolin-2-one
7-(piperidin-4-yloxy)-3,4-dihydroquinolin-2(1H)-one化学式
CAS
583031-08-7
化学式
C14H18N2O2
mdl
——
分子量
246.309
InChiKey
OPPALDRYWSWMFJ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.2
  • 重原子数:
    18
  • 可旋转键数:
    2
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    50.4
  • 氢给体数:
    2
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] HETEROCYCLIC COMPOUNDS POSSESSING AFFINITY AT 5HT1-TYPE RECEPTORS AND USE THEREOF IN THERAPY<br/>[FR] COMPOSES PRESENTANT UNE AFFINITE AVEC DES RECEPTEURS DE TYPE 5HT1 ET LEUR UTILISATION THERAPEUTIQUE
    申请人:GLAXO GROUP LTD
    公开号:WO2003068772A1
    公开(公告)日:2003-08-21
    Compounds of formula (I) and pharmaceutically acceptable salts thereof are disclosed:(I)wherein A is optionally substituted phenyl, naphthyl, indolyl, quinolinyl, quinazolinyl, indazolyl, isoquinolinyl or benzofuranyl; b is 1, 2 or 3 and c is 1, 2 or 3, wherein b + c is 2, 3, 4 or 5; X is carbon, Y is CH, is a double bond and e is 0; or X is carbon, Y is CH2 or oxygen, is a single bond and e is 1; or X is nitrogen, Y is CH2, is a single bond and e is 0; R1 is hydrogen, cyano, halogen, C1-6alkyl, C1-6alkoxy, C1-6alkoxyC1-6alkyl, NHCOCH3 or OCONR5R6, wherein R5 and R6 are independently hydrogen or C1-6alkyl; R2 is halogen, cyano or C1-6alkoxy; d is 0, 1, 2 or 3; R3 is hydrogen, C1-6alkyl, C1-6alkanoyl, fluoroC1-6alkanoyl, C1-6alkylsulfonyl, fluoroC1-6alkylsulfonyl, carbamoyl, C1-6alkylcarbamoyl or arylC1-6alkyl; and R4, together with the nitrogen atom to which it is attached, forms an optionally substituted 5 to 7 membered heterocyclic group fused to the benzene ring, provided that when a compound of formula (I) has the following structure: wherein A, b, c, R1, e, X, Y, R2 and d are as defined above and R3 is hydrogen, C1-6alkyl or arylC1-6alkyl, then (i) X is carbon, Y is CH and is a double bond; or (ii) b and c are both 1; or (iii) the carbon atom adjacent to the oxo-substituted carbon atom in the morpholinyl ring, marked ' * ', is substituted. Methods of preparing the compounds and uses of the compounds in therapy, in particular for a CNS disorder such as depression or anxiety, are also disclosed.
    公开了式(I)的化合物及其药学上可接受的盐: (I)其中A是可选择取代的苯基、萘基、吲哚基、喹啉基、喹唑啉基、吲唑基、异喹啉基或苯并呋喃基;b为1、2或3,c为1、2或3,其中b+c为2、3、4或5;X为碳,Y为CH,为双键,e为0;或X为碳,Y为CH2或氧,为单键,e为1;或X为氮,Y为CH2,为单键,e为0;R1为氢、氰基、卤素、C1-6烷基、C1-6烷氧基、C1-6烷氧基C1-6烷基、NHCOCH3或OCONR5R6,其中R5和R6各自独立地为氢或C1-6烷基;R2为卤素、氰基或C1-6烷氧基;d为0、1、2或3;R3为氢、C1-6烷基、C1-6酰基、氟代C1-6酰基、C1-6烷基磺酰基、氟代C1-6烷基磺酰基、氨基甲酰基、C1-6烷基氨基甲酰基或芳基C1-6烷基;而当式(I)的化合物具有以下结构时:其中A、b、c、R1、e、X、Y、R2和d如上定义,而R3为氢、C1-6烷基或芳基C1-6烷基时,(i) X为碳,Y为CH,为双键;或(ii) b和c均为1;或(iii)在吗啉环中氧代取代的碳原子相邻的碳原子,标记为'*',被取代。还公开了制备这些化合物的方法以及这些化合物在治疗中的用途,特别是在中枢神经系统紊乱如抑郁症或焦虑症中的用途。
  • Heterocyclic compounds possessing affinity at 5ht1-type receptors and use thereof in therapy
    申请人:Harrington P Frank
    公开号:US20050085458A1
    公开(公告)日:2005-04-21
    Compounds of formula (I) and pharmaceutically acceptable salts thereof are disclosed: wherein A is optionally substituted phenyl, naphthyl, indolyl, quinolinyl, quinazolinyl, indazolyl, isoquinolinyl or benzofuranyl; b is 1, 2 or 3 and c is 1, 2 or 3, wherein b+c is 2, 3, 4 or 5; X is carbon, Y is CH, is a double bond and e is 0; or X is carbon, Y is CH 2 or oxygen, is a single bond and e is 1; or X is nitrogen, Y is CH 2 , is a single bond and e is 0; R1 is hydrogen, cyano, halogen, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 alkoxyC 1-6 alkyl, NHCOCH 3 or OCONR5R6, wherein R5 and R6 are independently hydrogen or C 1-6 alkyl; R2 is halogen, cyano or C 1-6 alkoxy; d is 0, 1, 2 or 3; R3 is hydrogen, C 1-6 alkyl, C 1-6 alkanoyl, fluoroC 1-6 alkanoyl, C 1-6 alkylsulfonyl, fluoroC 1-6 alkylsulfonyl, carbamoyl, C 1-6 alkylcarbamoyl or arylC 1-6 alkyl; and R4, together with the nitrogen atom to which it is attached, forms an optionally substituted 5 to 7 membered heterocyclic group fused to the benzene ring, provided that when a compound of formula (I) has the following structure: wherein A, b, c, R1, e, X, Y, R2 and d are as defined above and R3 is hydrogen, C 1-6 alkyl or arylC 1-6 alkyl, then (i) X is carbon, Y is CH and is a double bond; or (ii) b and c are both 1; or (iii) the carbon atom adjacent to the oxo-substituted carbon atom in the morpholinyl ring, marked “*”, is substituted. Methods of preparing the compounds and uses of the compounds in therapy, in particular for a CNS disorder such as depression or anxiety, are also disclosed.
    公开了式(I)的化合物及其药学上可接受的盐:其中,A是可选择取代的苯基,萘基,吲哚基,喹啉基,喹唑啉基,吲唑基,异喹啉基或苯并呋喃基;b为1、2或3,c为1、2或3,其中b+c为2、3、4或5;X为碳,Y为CH,为双键,e为0;或X为碳,Y为CH2或氧,为单键,e为1;或X为氮,Y为CH2,为单键,e为0;R1为氢、氰、卤素、C1-6烷基、C1-6烷氧基、C1-6烷氧基C1-6烷基、NHCOCH3或OCONR5R6,其中R5和R6独立地为氢或C1-6烷基;R2为卤素、氰或C1-6烷氧基;d为0、1、2或3;R3为氢、C1-6烷基、C1-6酰基、氟代C1-6酰基、C1-6烷基磺酰基、氟代C1-6烷基磺酰基、氨基甲酰基、C1-6烷基氨基甲酰基或芳基C1-6烷基;而R4与其连接的氮原子形成一个可选择取代的5到7元杂环基,与苯环融合,但当式(I)的化合物具有以下结构时,则需满足以下条件:其中,A、b、c、R1、e、X、Y、R2和d如上所定义,而R3为氢、C1-6烷基或芳基C1-6烷基,那么(i)X为碳,Y为CH,为双键;或(ii)b和c均为1;或(iii)在吗啉环中与氧代取代碳原子相邻的碳原子,标记为“*”,被取代。还公开了制备这些化合物的方法以及这些化合物在治疗中的用途,特别是在治疗中枢神经系统疾病如抑郁症或焦虑症中的用途。
  • Heterocyclic compounds possessing affinity at 5HT1 -type receptors and use thereof in therapy
    申请人:Glaxo Group Limited
    公开号:US07244726B2
    公开(公告)日:2007-07-17
    Compounds of formula (I) and pharmaceutically acceptable salts thereof are disclosed: wherein A is optionally substituted phenyl, naphthyl, indolyl, quinolinyl, quinazolinyl, indazolyl, isoquinolinyl or benzofuranyl; b is 1, 2 or 3 and c is 1, 2 or 3, wherein b+c is 2, 3, 4 or 5; X is carbon, Y is CH, is a double bond and e is 0; or X is carbon, Y is CH2 or oxygen, is a single bond and e is 1; or X is nitrogen, Y is CH2, is a single bond and e is 0; R1 is hydrogen, cyano, halogen, C1-6alkyl, C1-6alkoxy, C1-6alkoxyC1-6alkyl, NHCOCH3 or OCONR5R6, wherein R5 and R6 are independently hydrogen or C1-6alkyl; R2 is halogen, cyano or C1-6alkoxy; d is 0, 1, 2 or 3; R3 is hydrogen, C1-6alkyl, C1-6alkanoyl, fluoroC1-6alkanoyl, C1-6alkylsulfonyl, fluoroC1-6alkylsulfonyl, carbamoyl, C1-6alkylcarbamoyl or arylC1-6alkyl; and R4, together with the nitrogen atom to which it is attached, forms an optionally substituted 5 to 7 membered heterocyclic group fused to the benzene ring, provided that when a compound of formula (I) has the following structure: wherein A, b, c, R1, e, X, Y, R2 and d are as defined above and R3 is hydrogen, C1-6alkyl or arylC1-6alkyl, then (i) X is carbon, Y is CH and is a double bond; or (ii) b and c are both 1; or (iii) the carbon atom adjacent to the oxo-substituted carbon atom in the morpholinyl ring, marked “★”, is substituted. Methods of preparing the compounds and uses of the compounds in therapy, in particular for a CNS disorder such as depression or anxiety, are also disclosed.
    本文披露了化合物(I)的公式及其药学上可接受的盐:其中A为可选取的取代苯基、萘基、吲哚基、喹啉基、喹唑啉基、吲唑基、异喹啉基或苯并呋喃基;b为1、2或3,c为1、2或3,其中b+c为2、3、4或5;X为碳,Y为CH,为双键,e为0;或X为碳,Y为CH2或氧,为单键,e为1;或X为氮,Y为CH2,为单键,e为0;R1为氢、氰基、卤素、C1-6烷基、C1-6烷氧基、C1-6烷氧基C1-6烷基、NHCOCH3或OCONR5R6,其中R5和R6独立地为氢或C1-6烷基;R2为卤素、氰基或C1-6烷氧基;d为0、1、2或3;R3为氢、C1-6烷基、C1-6酰基、氟C1-6酰基、C1-6烷基磺酰基、氟C1-6烷基磺酰基、氨基甲酰基、C1-6烷基氨基甲酰基或芳基C1-6烷基;而R4与其连接的氮原子形成一个可选的取代的5到7成员杂环基团融合到苯环上,但当化合物(I)具有以下结构时:其中A、b、c、R1、e、X、Y、R2和d如上定义,而R3为氢、C1-6烷基或芳基C1-6烷基,则(i)X为碳,Y为CH,为双键;或(ii)b和c都为1;或(iii)在哌嗪环中氧代取代的碳原子相邻的碳原子,标记为“★”,被取代。本文还披露了制备这些化合物的方法以及这些化合物在治疗中的用途,特别是用于中枢神经系统障碍,如抑郁症或焦虑症。
  • ANTIDEPRESSANT HETEROARYL DERIVATIVES OF HETEROCYCLE-FUSED BENZODIOXANS
    申请人:Failli Amedeo A.
    公开号:US20090042874A1
    公开(公告)日:2009-02-12
    The invention provides compounds of the Formula: that are useful for the treatment of depression (including but not limited to major depressive disorder, childhood depression and dysthymia), anxiety, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder (also known as pre-menstrual syndrome), attention deficit disorder (with and without hyperactivity), obsessive compulsive disorder, social anxiety disorder, generalized anxiety disorder, obesity, eating disorders such as anorexia nervosa, bulimia nervosa, vasomotor flushing, cocaine and alcohol addiction, sexual dysfunction and related illnesses.
    该发明提供了下列式的化合物,该化合物对于治疗抑郁症(包括但不限于重度抑郁障碍、儿童抑郁症和心境不良)、焦虑症、恐慌症、创伤后应激障碍、经前期失调症(也称为经前综合征)、注意力缺陷多动障碍(有和没有过度活跃)、强迫症、社交焦虑障碍、广泛性焦虑障碍、肥胖症、饮食紊乱如厌食症、贪食症、潮红、可卡因和酒精成瘾、性功能障碍及相关疾病具有有益作用。
  • Heteroaryl piperidine ether allosteric modulators of the M4 muscarinic acetylcholine receptor
    申请人:Merck Sharp & Dohme Corp.
    公开号:US11319298B2
    公开(公告)日:2022-05-03
    The present invention is directed to heteroarylpiperidine ether compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M4 muscarinic acetylcholine receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.
    本发明涉及杂芳基哌啶醚化合物,它们是 M4 毒蕈碱乙酰胆碱受体的异构调节剂。本发明还涉及本文所述化合物在潜在治疗或预防涉及 M4 肌 肉碱乙酰胆碱受体的神经和精神疾病中的用途。本发明还涉及包含这些化合物的组合物。本发明还涉及这些组合物在潜在预防或治疗涉及 M4 蕈样乙酰胆碱受体的此类疾病中的用途。
查看更多